• FDA approves Dalvance for pediatric ABSSSI treatment

    1 month ago - By Healio

    The FDA approved the AbbVie's Dalvance for the treatment of acute bacterial skin and skin structure infections in pediatric patients from birth, according to a press release.
    Dalvance is the first single-dose option administered as a 30-minute intravenous infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections from MRSA, the company said.
    The approval was based on results from a multi-center, open-label, actively controlled clinical trial evaluating Dalvance in pediatric patients from birth to
    Read more ...

     

  • IV Antibiotic Approved for Kids With Skin Infections

    IV Antibiotic Approved for Kids With Skin Infections

    1 month ago - By MedPageToday

    Antibiotic dalbavancin , previously approved to treat bacterial skin infections in adults, received FDA approval for the pediatric population from birth, manufacturer AbbVie said in a press release on Friday.
    Dalbavancin...
    Read more ...